The estimated Net Worth of Steven A J Salamon is at least $11.2 millió dollars as of 19 March 2024. Mr. Salamon owns over 26,882 units of Delcath Systems stock worth over $11,165,409 and over the last 4 years he sold DCTH stock worth over $0. In addition, he makes $0 as Independent Director at Delcath Systems.
Sign up
Mr. Salamon DCTH stock SEC Form 4 insiders trading
Steven has made over 14 trades of the Delcath Systems stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 26,882 units of DCTH stock worth $100,001 on 19 March 2024.
The largest trade he's ever made was buying 26,882 units of Delcath Systems stock on 19 March 2024 worth over $100,001. On average, Steven trades about 3,425 units every 51 days since 2020. As of 19 March 2024 he still owns at least 1,121,025 units of Delcath Systems stock.
You can see the complete history of Mr. Salamon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Salamon biography
Steven Salamon serves as Independent Director of the Company. Mr. Salamon is a co-founder of and has served as Portfolio Manager at Rosalind Advisors, Inc., a life sciences focused investment manager (“Rosalind Advisors”), since 2006. Mr. Salamon holds a MBA from the Ivey Business School and an Engineering Physics degree from the University of Toronto. Prior to co-founding Rosalind Advisors, Mr. Salamon worked as an equity analyst at HSBC Securities and RBC Capital Markets (formerly RBC Dominion Securities). In addition, Mr. Salamon provides a valuable stockholder perspective to the Board.
How old is Steven Salamon?
Steven Salamon is 55, he's been the Independent Director of Delcath Systems since 2020. There are 7 older and 1 younger executives at Delcath Systems. The oldest executive at Delcath Systems, Inc. is Roger Stoll, 78, who is the Non-Executive Independent Chairman of the Board.
What's Steven Salamon's mailing address?
Steven's mailing address filed with the SEC is 15 WELLESLEY STREET WEST, SUITE 326, , TORONTO, A6, M4Y 0G7.
Insiders trading at Delcath Systems
Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel és Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.
What does Delcath Systems do?
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
What does Delcath Systems's logo look like?
Complete history of Mr. Salamon stock trades at Delcath Systems
Delcath Systems executives and stock owners
Delcath Systems executives and other stock owners filed with the SEC include:
-
John Purpura,
Chief Operating Officer, Executive Vice President - Global Head of Operations -
John Purpura M.S.,
Chief Operating Officer -
Gerard J. Michel,
CEO & Director -
Roger Stoll,
Non-Executive Independent Chairman of the Board -
John Sylvester,
Independent Director -
Steven Salamon,
Independent Director -
Elizabeth Czerepak,
Independent Director -
Gilad Aharon,
Independent Director -
Christine Padula,
Interim Principal Accounting Officer -
Gerard Michel,
Chief Executive Officer, Director -
Dr. Johnny John M.D.,
Sr. VP Clinical Devel. & Medical Affairs -
Robin Wagge,
Sr. VP of Rubenstein Associates -
Thomas Johnson,
Sr. Director of Corp. Communications -
Bridget A Martell,
-
Gil Aharon,
-
Advisors, Inc. Rosalind,
Director -
Anthony Dias,
VP FINANCE -
Advisors, Inc.Aharon Gil Sa...,
-
Johnny John,
SVP CLINICAL DEV & MED AFFAIRS -
Jennifer K. Simpson,
President and CEO -
William Dodge Rueckert,
Director -
Marco Taglietti,
Director -
Barbra Keck,
Chief Financial Officer -
Advisors, Inc.Salamon Steve...,
-
Martha S. Rook,
CHIEF OPERATING OFFICER -
Vojo Vukovic,
CHIEF MEDICAL OFFICER -
Kevin Muir,
GM INTERVENTIONAL ONCOLOGY -
David L. Hoffman,
GEN'L COUNSEL, CCO & SECY